Expand all sections

Atezolizumab

Tecentriq

Extended indication Borstkanker (triple negative BC).
Therapeutic value No judgement
Total cost 5,000,000.00

Product

Active substance Atezolizumab
Domain Oncology and Hematology
Main indication Breast cancer
Extended indication Borstkanker (triple negative BC).
Proprietary name Tecentriq
Manufacturer Roche
Route of administration Intravenous
Therapeutical formulation Intravenous drip
Budgetting framework Intermural (MSZ)

Registration

Registration route Centralised (EMA)
Expected Registration 2020
Orphan drug No
Additional remarks Dit is een indicatie-uitbreiding. Sluis-product.

Therapeutic value

Therapeutic value No judgement
Duration of treatment Not found

Expected patient volume per year

Patient volume

< 100

Market share is generally not included unless otherwise stated.
References NKR
Additional remarks NKR 2015: 100 diagnoses mammacarcinoom HR-, HER-, stadium 4

Expected cost per patient per year

Cost 40,000.00 - 60,000.00
References Medicijnkosten.nl; drugs.com
Additional remarks Verwacht in lijn met andere immunotherapieën. €1098,16 voor nivolumab 10mg per ml fl 10 ml; €3355,96 voor pembrolizumab 25 mg per ml fl 4ml. In de VS $9.000 dollar voor 1200 mg 20 ml.

Potential total cost per year

Total cost

5,000,000.00

This amount gives an indication of the total cost. It is the result of the average expected patient volume times the average cost per patient. both per year.

Off label use

There is currently nothing known about off label use.

Indication extension

Indication extension Yes
Indication extensions Er lopen meerdere PhIII studies.

Other information

There is currently no futher information available.